Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Brainomix United Kingdom England

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix's AI-powered e-Lung software and biomarkers to uncover novel insightsPublished data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measuresView original content:https://www.prnewswire.co.uk/news-releases/data-from-brainomixs-collaboration-with-astrazeneca-shows-its-ai-powered-e-lung-better-identifies-lung-fibrosis-patients-at-risk-of-decline-302100025.html